| Title: |
Diagnostic value of cellular inflammatory markers in CNS tumor patients undergoing glucocorticoid therapy |
| Authors: |
Sklyar, Sofia; Sitovskaya, Daria; Dryagina, Nataliya; Ulitin, Alexei; Olyushin, Victor; Combs, Stephanie E.; Samochernykh, Konstantin; Shevtsov, Maxim |
| Contributors: |
Deutsche Forschungsgemeinschaft |
| Source: |
Frontiers in Oncology ; volume 16 ; ISSN 2234-943X |
| Publisher Information: |
Frontiers Media SA |
| Publication Year: |
2026 |
| Collection: |
Frontiers (Publisher - via CrossRef) |
| Description: |
Introduction While inflammation is recognized as a key driver of solid tumor progression, the diagnostic and pathophysiological relevance of cellular inflammatory biomarkers in central nervous system (CNS) neoplasms remains incompletely defined. Materials and methods Clinical and hematological data were analyzed from 44 patients with glioblastoma, 32 with brain metastases, and 33 patients with meningioma who underwent primary surgical treatment between 2024 and 2025. A control group of healthy age-matched volunteers (n = 20) was included for comparison. The diagnostic performance of cellular inflammatory markers was evaluated across tumor entities, with additional stratification according to glucocorticosteroid exposure. Results Patients with intracerebral tumors exhibited higher neutrophil and monocyte counts, as well as elevated neutrophil-to-lymphocyte ratio (NLR) and pan-immune inflammation value (PIV), along with a lower lymphocyte-to-monocyte ratio (LMR) compared to both the meningioma group and healthy volunteers (p |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| DOI: |
10.3389/fonc.2026.1764339 |
| DOI: |
10.3389/fonc.2026.1764339/full |
| Availability: |
https://doi.org/10.3389/fonc.2026.1764339; https://www.frontiersin.org/articles/10.3389/fonc.2026.1764339/full |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.C094B30 |
| Database: |
BASE |